A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.

[1]  F. Cianchi,et al.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer , 2020, Translational oncology.

[2]  F. Pontén,et al.  CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup , 2020, Frontiers in Oncology.

[3]  M. Fassan,et al.  The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer , 2020, Cancer Cell International.

[4]  S. Cascinu,et al.  BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights , 2019, International journal of molecular sciences.

[5]  A. Falcone,et al.  BRAF mutant metastatic colorectal cancers: new arrows in our quiver. , 2019, Annals of translational medicine.

[6]  R. Epstein,et al.  Impact of Prognostic Discussions on the Patient-Physician Relationship: Prospective Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Gerlinger,et al.  Treatment and Survival Outcome of BRAF‐Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case‐Control Study , 2017, Clinical colorectal cancer.

[8]  M. Kendrick,et al.  Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. , 2017, The oncologist.

[9]  Jeffrey S. Morris,et al.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes , 2017, Clinical Cancer Research.

[10]  M. Nichelatti,et al.  Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis , 2017, Clinical colorectal cancer.

[11]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Scheithauer,et al.  Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. , 2017, European journal of cancer.

[13]  S. Jaeger,et al.  A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. , 2017, Cancer discovery.

[14]  L. Diaz,et al.  Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). , 2017 .

[15]  P. Quirke,et al.  Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Tournigand,et al.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. , 2016, The Lancet. Oncology.

[17]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Sabine Tejpar,et al.  BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression , 2016, Clinical Cancer Research.

[19]  Laura Ferrari,et al.  Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer , 2015, British Journal of Cancer.

[20]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[21]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Gibbs,et al.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Tu,et al.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. , 2015, European journal of cancer.

[24]  M. Rugge,et al.  BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection , 2015, British Journal of Cancer.

[25]  C. Brigand,et al.  KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer , 2015, British Journal of Cancer.

[26]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[27]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. , 2014, European journal of cancer.

[28]  M. Kalady,et al.  BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta‐analysis , 2013, Colorectal Disease.

[29]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[30]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[31]  J. Barrett,et al.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[33]  D. Sargent,et al.  Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[35]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[36]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .